E6AP promotes prostate cancer by reducing p27 expression

被引:24
作者
Raghu, Dinesh [1 ,2 ]
Paul, Piotr Jan [1 ,2 ]
Gulati, Twishi [1 ,2 ]
Deb, Siddhartha [3 ]
Khoo, Christine [4 ]
Russo, Andrea [5 ]
Gallo, Enzo [5 ]
Blandino, Giovanni [6 ]
Chan, Ai-Leen [2 ,11 ]
Takano, Elena [4 ]
Sandhu, Shahneen K. [7 ]
Fox, Stephen B. [4 ]
Williams, Scott [8 ]
Haupt, Sue [1 ,2 ]
Gamell, Cristina [1 ,2 ]
Haupt, Ygal [1 ,2 ,9 ,10 ]
机构
[1] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Tumor Suppress Lab, Melbourne, Vic, Australia
[3] Anatpath Serv Pty Ltd, Gardenvale, Vic, Australia
[4] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[5] Regina Elena Inst Canc Res, Dept Surg Pathol, Rome, Italy
[6] Italian Natl Canc Inst, Oncogen & Epigenet Unit, Rome, Italy
[7] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[8] Peter MacCallum Canc Ctr, Div Radiat Oncol & Canc Imaging, Melbourne, Vic, Australia
[9] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[10] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia
[11] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
prostate cancer; E6AP; p27; E2F1; tumor suppression; BORTEZOMIB; P27(KIP1); UBIQUITIN; PROTEIN; COACTIVATOR; DEGRADATION; DOCETAXEL; TRIAL;
D O I
10.18632/oncotarget.17224
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PC) is the most common cancer in men. Elevated levels of E3 ligase, E6-Associated Protein (E6AP) were previously linked to PC, consistent with increased protein expression in a subset of PC patients. In cancers, irregular E3 ligase activity drives proteasomal degradation of tumor suppressor proteins. Accordingly, E3 ligase inhibitors define a rational therapy to restore tumor suppression. The relevant tumor suppressors targeted by E6AP in PC are yet to be fully identified. In this study we show that p27, a key cell cycle regulator, is a target of E6AP in PC. Down regulation of E6AP increases p27 expression and enhances its nuclear accumulation in PC. We demonstrate that E6AP regulates p27 expression by inhibiting its transcription in an E2F1-dependent manner. Concomitant knockdown of E6AP and p27 partially restores PC cell growth, supporting the contribution of p27 to the overall effect of E6AP on prostate tumorigenesis. Overall, we unravelled the E6AP-p27 axis as a new promoter of PC, exposing an attractive target for therapy through the restoration of tumor suppression.
引用
收藏
页码:42939 / 42948
页数:10
相关论文
共 33 条
  • [1] HPV E6, E6AP and cervical cancer
    Beaudenon, Sylvie
    Huibregtse, Jon M.
    [J]. BMC BIOCHEMISTRY, 2008, 9
  • [2] Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death
    Birch, S. E.
    Kench, J. G.
    Takano, E.
    Chan, P.
    Chan, A. -L.
    Chiam, K.
    Veillard, A. -S.
    Stricker, P.
    Haupt, S.
    Haupt, Y.
    Horvath, L.
    Fox, S. B.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (12) : 2392 - 2397
  • [3] Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
    Chen, D.
    Frezza, M.
    Schmitt, S.
    Kanwar, J.
    Dou, Q. P.
    [J]. CURRENT CANCER DRUG TARGETS, 2011, 11 (03) : 239 - 253
  • [4] Cheville JC, 1998, MODERN PATHOL, V11, P324
  • [5] The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
    Chu, Isabel M.
    Hengst, Ludger
    Slingerland, Joyce M.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (04) : 253 - 267
  • [6] Proteasome inhibitors in cancer therapy
    Crawford, Lisa J.
    Walker, Brian
    Irvine, Alexandra E.
    [J]. JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2011, 5 (02) : 101 - 110
  • [7] Ubiquitin and control of transcription
    Dhananjayan, SC
    Ismail, A
    Nawaz, Z
    [J]. ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 : 69 - 80
  • [8] Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
    Di Cristofano, A
    De Acetis, M
    Koff, A
    Cordon-Cardo, C
    Pandolfi, PP
    [J]. NATURE GENETICS, 2001, 27 (02) : 222 - 224
  • [9] Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer
    Dreicer, Robert
    Petrylak, Daniel
    Agus, David
    Webb, Iain
    Roth, Bruce
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1208 - 1215
  • [10] Drobnjak M, 2003, CLIN CANCER RES, V9, P2613